D Schanzer1, L Pogany1, J Aho1, K Tomas1, M Gale-Rowe1, J C Kwong2,3,4,5, N Z Janjua6,7, J Feld8,9. 1. Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON. 2. Institute for Clinical Evaluative Sciences, Toronto, ON. 3. Public Health Ontario, Toronto, ON. 4. Department of Family & Community Medicine, University of Toronto, Toronto, ON. 5. Dalla Lana School of Public Health, University of Toronto, Toronto, ON. 6. BC Centre for Disease Control, Vancouver, BC. 7. School of Population and Public Health, University of British Columbia, Vancouver, BC. 8. Toronto Centre for Liver Disease, University Health Network, Toronto General Hospital, Toronto, ON. 9. Sandra Rotman Centre, University of Toronto, Toronto, ON.
Abstract
BACKGROUNDS: Hospitalizations associated with hepatitis C virus (HCV) infection and liver disease increased on average by 6.0% per year from 2004 to 2010 in Canada and were projected (in 2010) to increase by another 4% by 2016. The first generation of direct-acting antivirals (DAAs) became available in 2012. In 2014, a second generation of effective and well-tolerated DAA therapy was authorized in Canada. The impact of DAA therapy on the HCV-associated disease burden in Canada has not been documented. OBJECTIVES: To assess the potential impact of DAA therapy on the disease burden by a) comparing the actual hospitalization rates associated with HCV infection and liver disease following the introduction of DAAs in Canada with the 2010 baseline projection and b) documenting the associated uptake of anti-HCV therapy. METHODS: The hospital records of inpatients diagnosed with chronic HCV and chronic liver disease were extracted from the Canadian Discharge Abstract Database (DAD) by fiscal year for 2004-2016. We compared the actual number of hospitalizations to the baseline projection by year and for selected 5-year birth cohorts (1925-1989). The monthly number of new prescriptions for anti-HCV regimens was extracted from the IQVIA CDH CompuScript database (formerly IMS Health), aggregated to annual levels by age group and compared with hospitalization trends. RESULTS: Compared to the baseline projection, there was a slight reduction in hospitalizations in 2014/15 and 2015/16. This slight reduction was followed by a more significant decline in 2016/17 (32% below expected; 95% confidence interval [CI]: 27%-37%). The largest declines were observed for patients born before 1960 (age 55 or older) at 40% below expected in 2016/17. The number of new anti-HCV prescriptions increased from 5,484 in fiscal year 2012/13 to a peak of 17,775 in 2015/2016. The number of new prescriptions corresponds to approximately 1.3 and five times the number of hospitalizations in 2012/13 and 2015/16, respectively. CONCLUSIONS: In Canada there has been a modest decrease in HCV and liver-related hospitalizations following a significant increase in uptake of second-generation DAAs in 2015. However, the burden is still high. Linked health administrative databases created to monitor the disease burden in the new treatment era should provide additional insight with the linkage of treatment history and disease stage to individual outcomes.
BACKGROUNDS: Hospitalizations associated with hepatitis C virus (HCV) infection and liver disease increased on average by 6.0% per year from 2004 to 2010 in Canada and were projected (in 2010) to increase by another 4% by 2016. The first generation of direct-acting antivirals (DAAs) became available in 2012. In 2014, a second generation of effective and well-tolerated DAA therapy was authorized in Canada. The impact of DAA therapy on the HCV-associated disease burden in Canada has not been documented. OBJECTIVES: To assess the potential impact of DAA therapy on the disease burden by a) comparing the actual hospitalization rates associated with HCV infection and liver disease following the introduction of DAAs in Canada with the 2010 baseline projection and b) documenting the associated uptake of anti-HCV therapy. METHODS: The hospital records of inpatients diagnosed with chronic HCV and chronic liver disease were extracted from the Canadian Discharge Abstract Database (DAD) by fiscal year for 2004-2016. We compared the actual number of hospitalizations to the baseline projection by year and for selected 5-year birth cohorts (1925-1989). The monthly number of new prescriptions for anti-HCV regimens was extracted from the IQVIA CDH CompuScript database (formerly IMS Health), aggregated to annual levels by age group and compared with hospitalization trends. RESULTS: Compared to the baseline projection, there was a slight reduction in hospitalizations in 2014/15 and 2015/16. This slight reduction was followed by a more significant decline in 2016/17 (32% below expected; 95% confidence interval [CI]: 27%-37%). The largest declines were observed for patients born before 1960 (age 55 or older) at 40% below expected in 2016/17. The number of new anti-HCV prescriptions increased from 5,484 in fiscal year 2012/13 to a peak of 17,775 in 2015/2016. The number of new prescriptions corresponds to approximately 1.3 and five times the number of hospitalizations in 2012/13 and 2015/16, respectively. CONCLUSIONS: In Canada there has been a modest decrease in HCV and liver-related hospitalizations following a significant increase in uptake of second-generation DAAs in 2015. However, the burden is still high. Linked health administrative databases created to monitor the disease burden in the new treatment era should provide additional insight with the linkage of treatment history and disease stage to individual outcomes.
Entities:
Keywords:
disease burden; hepatitis C; hospitalization; monitoring the impact of DAA treatment; trends
Authors: Adriaan J van der Meer; Jordan J Feld; Harald Hofer; Piero L Almasio; Vincenza Calvaruso; Conrado M Fernández-Rodríguez; Soo Aleman; Nathalie Ganne-Carrié; Roberta D'Ambrosio; Stanislas Pol; Maria Trapero-Marugan; Raoel Maan; Ricardo Moreno-Otero; Vincent Mallet; Rolf Hultcrantz; Ola Weiland; Karoline Rutter; Vito Di Marco; Sonia Alonso; Savino Bruno; Massimo Colombo; Robert J de Knegt; Bart J Veldt; Bettina E Hansen; Harry L A Janssen Journal: J Hepatol Date: 2016-10-22 Impact factor: 25.083
Authors: Robert P Myers; Mel Krajden; Marc Bilodeau; Kelly Kaita; Paul Marotta; Kevork Peltekian; Alnoor Ramji; Chris Estes; Homie Razavi; Morris Sherman Journal: Can J Gastroenterol Hepatol Date: 2014-05
Authors: Jeffrey D Stanaway; Abraham D Flaxman; Mohsen Naghavi; Christina Fitzmaurice; Theo Vos; Ibrahim Abubakar; Laith J Abu-Raddad; Reza Assadi; Neeraj Bhala; Benjamin Cowie; Mohammad H Forouzanfour; Justina Groeger; Khayriyyah Mohd Hanafiah; Kathryn H Jacobsen; Spencer L James; Jennifer MacLachlan; Reza Malekzadeh; Natasha K Martin; Ali A Mokdad; Ali H Mokdad; Christopher J L Murray; Dietrich Plass; Saleem Rana; David B Rein; Jan Hendrik Richardus; Juan Sanabria; Mete Saylan; Saeid Shahraz; Samuel So; Vasiliy V Vlassov; Elisabete Weiderpass; Steven T Wiersma; Mustafa Younis; Chuanhua Yu; Maysaa El Sayed Zaki; Graham S Cooke Journal: Lancet Date: 2016-07-07 Impact factor: 79.321
Authors: Jeffrey C Kwong; Sujitha Ratnasingham; Michael A Campitelli; Nick Daneman; Shelley L Deeks; Douglas G Manuel; Vanessa G Allen; Ahmed M Bayoumi; Aamir Fazil; David N Fisman; Andrea S Gershon; Effie Gournis; E Jenny Heathcote; Frances B Jamieson; Prabhat Jha; Kamran M Khan; Shannon E Majowicz; Tony Mazzulli; Allison J McGeer; Matthew P Muller; Abhishek Raut; Elizabeth Rea; Robert S Remis; Rita Shahin; Alissa J Wright; Brandon Zagorski; Natasha S Crowcroft Journal: PLoS One Date: 2012-09-04 Impact factor: 3.240
Authors: Claire E Kendall; Michael Fitzgerald; Jessy Donelle; Jeffrey C Kwong; Chrissi Galanakis; Rob Boyd; Curtis L Cooper Journal: Can Liver J Date: 2020-06-04